Biocon Ltd, in collaboration with its European partner Zentiva, has obtained decentralised procedure approval in the European Union for their complex formulation, Liraglutide, which is used to manage diabetes and support weight management.
The approval covers generic versions of Victoza, indicated for treating Type-2 Diabetes, and Saxenda, used for weight management, Biocon Ltd stated in a regulatory filing.
Victoza and Saxenda are trademarks owned by Novo Nordisk.
In a strategic move aimed at reviving its performance in the Indian market, Nissan has announced a key leadership transition. Effective August 1, Saurabh Vatsa, Managing Director of Nissan Motor India, will...
Lavasa, the ambitious private city rising near Pune and just a three-hour drive from Mumbai, was envisioned as both a nod to the past and a leap into the future. Touted as...
In an effort to boost travel during the traditionally slow monsoon season, travel platforms, airlines, and accommodation providers are rolling out attractive monsoon sales. These promotions aim to tap into the growing...
The credit card market saw a much-needed lift in May, thanks to holiday travel, with spending rising to ₹1.9 lakh crore — a 3% jump from April and a robust 15% increase...
Industry Insights Magazine delivers expert analysis, trends, and startup stories across sectors like Finance, Healthcare, Manufacturing, and Real Estate. With curated interviews, case studies, and reports, we empower professionals and entrepreneurs with actionable insights, helping them navigate change, discover opportunities, and lead confidently in today’s dynamic business landscape.
Discussion about this post